US OptionsDetailed Quotes
TTOO250117P500
- 0.40
- 0.000.00%
15min DelayClose Oct 13 16:00 ET
0.00High0.00Low
0.00Open0.40Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV60.00%PremiumJan 17, 2025Expiry Date0.25Intrinsic Value100Multiplier-6DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
T2 Biosystems Stock Discussion
Voting instructions must be received by: March 2, 2025 11:59 PM Eastern Time
Your vote has been recorded as follows:
ProposalYour Election1.To approve an amendment to the Company's restated certificate of incorporation to effect a reverse stock split of the Company's common stock, par value $0.001 per share (the "Common Stock") at a reverse split ratio ranging from any whole number between and including 1-for-10 and 1-for-100, with the exact ratio within su...
FYI tstocks called everyone to buy $T2 Biosystems (TTOO.US)$ in 2023:
At that time $T2 Biosystems (TTOO.US)$ was trading around $30
Now, it is trading at $0.39
Let that sink in. Do your own due dilligence.
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
sepsis tests
Benzinga· 5 mins ago
The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria Panel, the T2Candida Panel, and the T2Resistance Panel. The target hospitals for the new instruments include:
Selling a second T2Dx Instrument to a major reference hospital to expand "same store" sales;Selling the first T2Dx Instrument to...
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
Tuesday, 17th December at 9:00 am
LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company...
No comment yet